Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27508531 | 0.89 | TSHR (0.51) | TSHRMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL29289884 | 0.89 | BRD4 (0.53) | TSHRMAPTALDH1A1FAAHCYP3A4 | |
| SCHEMBL17518849 | 0.87 | MAPK1 (0.49) | MAPTRAB9ASMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL3895476 | 0.86 | TSHR (0.66) | TSHRMAPTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL20027767 | 0.84 | TSHR (0.53) | TSHRMAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL17150491 | 0.83 | PDK1 (0.56) | MAPTRAB9ASMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL14368009 | 0.83 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL4599990 | 0.82 | LOXL2 (0.57) | RAB9ASMN1; SMN2ALDH1A1FAAHCYP3A4 | |
| SCHEMBL11162961 | 0.82 | MAPK1 (0.50) | MAPTRAB9ASMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL1697114 | 0.81 | ENPP2 (0.60) | RAB9ASMN1; SMN2ALDH1A1FAAHCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765993-B2 | One-pot production of carbamates using solid catalysts | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2014-07-01 | — | — | US | disclosed |
| US-20120053359-A1 | ONE-POT PRODUCTION OF CARBAMATES USING SOLID CATALYSTS | UNIVERSIDAD POLITECNICA DE VALENCIA (ES) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053359-A1 | ONE-POT PRODUCTION OF CARBAMATES USING SOLID CATALYSTS | CA7, CA2, CA4 | TSHR 3643/4885MAPT 2767/4885RAB9A 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.